Dr. Abud Bakri

But it's very easy, right?

The data are there.

No, no, it's all there.

It's there.

Like I started to care about the thymus post-pandemic because I noticed people's lymphocyte counts were lower.

And I could notice that, you know, anecdotally or looking at, you know, small data sets, like, hey, people that had lower lymphocyte counts had worse disease or like it.

earlier, like people that had cancers in their late 30s, early 40s.

I'm like, huh, they all had like lower lymphocyte counts.

So I started to like dig into the literature.

And I'm lobbying a lot of the hematologists and infectious disease doctors in my hospital to start to look at this.

Unfortunately, they kind of are textbook.

It's not part of the guidelines.

It's in a space that's not pathology.

So it's not clear like, hey, if I check your lymphocyte to monocyte count right now, is it going to change my management of you in the hospital today?

Not really.

It's more of a long-term look.

So that's where all these direct-to-health, direct-to-consumer companies have an opportunity to kind of modulate the way medicine is practiced in the United States.

But if we have this metric that we can study, why not use it and then try different interventions and see what actually helps people?

Like we've gotten sometimes peptides.

We've had people go from like a 4-to-1 lymphocyte to monocyte ratio to an 8-to-1 ratio.